Avitar Enters Rapidly Expanding Oral Fluid-Based Laboratory Drug Testing Market

Avitar Continues Track Record of Innovation and Improves Company's Ability to

Compete in $1.5B Drug Testing Market



Nov 29, 2005, 00:00 ET from Avitar, Inc.

    CANTON, Mass., Nov. 29 /PRNewswire-FirstCall/ -- Avitar, Inc.
 (OTC Bulletin Board:   AVRN) ("Avitar" or the "Company") developer of the
 world's first oral fluid-based, on-site screen for drugs-of-abuse, today
 announced ORALscreenLAB(TM), a comprehensive array of laboratory-based oral
 fluid drug screens.  With the addition of ORALscreenLAB (see more detailed
 product information below), Avitar now offers the industry's widest selection
 of oral fluid-based solutions to combat drug abuse.
     "Our goal is to provide employers with all the necessary tools to
 significantly reduce the incidences of drug abuse on the job," said Peter
 Phildius, Chairman and CEO of Avitar.  "Industry experts recognize that random
 drug screening is an extremely effective deterrent to drug abuse, however,
 traditional urine testing is not well suited for random screening in the
 corporate sector.  Oral fluid-based testing is an enabling technology that
 provides corporations with a key component in establishing an effective drug-
 free workplace program."
     Phildius explained, "Oral fluid-based technology removes the barriers to
 random testing associated with urine.  For example, urine drug testing
 presents gender issues, problems with sample substitution or adulteration
 (beating the test), and a general lack of social acceptance and convenience.
 Observed, on-site, oral fluid collection also eliminates the costly employee
 downtime associated with specialized urine collection facilities.  With the
 addition of ORALscreenLAB to our comprehensive group of drug tests and
 consulting services, Avitar is becoming a single source company for oral
 fluid-based drug free workplace solutions."
     In practice, oral fluid-based testing for drugs-of-abuse has proven to be
 most efficient for organizations looking to reduce workplace drug use.
 Research shows that oral fluid testing yields results that are comparable in
 accuracy to urine tests, and can detect the presence of virtually all drugs
 within minutes of consumption.  Avitar will continue to focus its marketing
 and sales efforts on its on-site ORALscreen(R) DRUGOMETER(TM).  ORALscreenLAB,
 however, presents a viable option to corporations wishing to step away from
 urine testing, but are not yet ready to implement on-site testing technology.
 
     About Avitar
     Avitar, Inc. develops, manufactures and markets innovative and proprietary
 products.  Their field includes the oral fluid diagnostic market, the disease
 and clinical testing market, and customized polyurethane applications used in
 the wound dressing industry.  Avitar manufactures ORALscreen(R), the world's
 first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well
 as HYDRASORB(R), an absorbent topical dressing for moderate to heavy exudating
 wounds.  Avitar is also developing diagnostic strategies for disease and
 clinical testing in the estimated $25 billion in-vitro diagnostics market.
 Conditions targeted include influenza, diabetes, and pregnancy.  For more
 information, see Avitar's website at http://www.avitarinc.com.
 
     Safe Harbor Statement. This release contains forward looking statements
 that are subject to risks and uncertainties including the development and
 marketing of new applications and other risks that are detailed from time to
 time in the Company's filings with the Securities and Exchange Commission.  In
 view of such risks and uncertainties, the Company's actual results could
 differ materially from those anticipated in such forward looking statements.
 
     Product Information: ORALscreenLAB
     Based upon the most recent statistics published by Quest Diagnostics,
 Inc., one of the nations leading test laboratories, ORALscreenLAB tests for
 99% of drugs typically found in the private U.S. workplace sector.
 ORALscreenLab is an inclusive laboratory-based screen and GS/MS confirmation
 test.  The solution is available in the three versions shown below.
 
     * ORALscreen LAB5+
       Amphetamines: (Dexedrine(R)), MDA (Love Pill), MDEA (Eve)
       Methamphetamines: (Desoxyn(R)), MDMA, Ecstasy
       THC: Delta-9-tetrahydrocannabinol (CAS No. 1972-08-3)
       Cocaine: Benzoylecgonine, (Coke)
       Opiates: Morphine (Durapmorph(R)), Codeine (Methylmorphine), 6-AM,
       Hydrocodone (Vicodin(R)), Hydromorphone (Dilaudid(R)), Oxycodone
       (Oxycontin(R), Percoset(R)), Oxymorphone (Nurmophan(R)), Dihydrocodeine
       PCP: Phencyclidine (Angel Dust)
 
     * ORALscreen LAB7 -- Detects: All drugs tested by ORALscreenLAB5+, and
       Benzodiazepines: Alprazolam (Xanax(R)), Clonazepam (Klonopin(R)),
       Chlordiazepoxide (Librium(R)), Diazepam (Valium(R)), Lorazepam
       (Avitvan(R)), Temazepam(Restoril(R)), Oxazepam (Serax(R)),Nordiazepam
       (Tranxene(R))
       Propoxyphene: (Darvon(R))
 
     * ORALscreen LAB8 -- Detects: All drugs tested by ORALscreenLAB7, and
       Barbiturates: Amobarbital (Amytal(R)), Butabarbital (Butisol(R))
       Pentobarbital (Nembutal(R)), Phenobarbital (Luminal(R)), Secobarbital
       (Seconal(R)), Butalbital (Fiorinal(R))
 
 
      Company Contact:                     PR Contact:
      Peter Cholakis                       Maura Landry
      Avitar Inc.                          SHIFT Communications
      781-821-2440 x117                    617-681-1229
      pcholakis@avitarinc.com              mlandry@shiftcomm.com
 
 

SOURCE Avitar, Inc.
    CANTON, Mass., Nov. 29 /PRNewswire-FirstCall/ -- Avitar, Inc.
 (OTC Bulletin Board:   AVRN) ("Avitar" or the "Company") developer of the
 world's first oral fluid-based, on-site screen for drugs-of-abuse, today
 announced ORALscreenLAB(TM), a comprehensive array of laboratory-based oral
 fluid drug screens.  With the addition of ORALscreenLAB (see more detailed
 product information below), Avitar now offers the industry's widest selection
 of oral fluid-based solutions to combat drug abuse.
     "Our goal is to provide employers with all the necessary tools to
 significantly reduce the incidences of drug abuse on the job," said Peter
 Phildius, Chairman and CEO of Avitar.  "Industry experts recognize that random
 drug screening is an extremely effective deterrent to drug abuse, however,
 traditional urine testing is not well suited for random screening in the
 corporate sector.  Oral fluid-based testing is an enabling technology that
 provides corporations with a key component in establishing an effective drug-
 free workplace program."
     Phildius explained, "Oral fluid-based technology removes the barriers to
 random testing associated with urine.  For example, urine drug testing
 presents gender issues, problems with sample substitution or adulteration
 (beating the test), and a general lack of social acceptance and convenience.
 Observed, on-site, oral fluid collection also eliminates the costly employee
 downtime associated with specialized urine collection facilities.  With the
 addition of ORALscreenLAB to our comprehensive group of drug tests and
 consulting services, Avitar is becoming a single source company for oral
 fluid-based drug free workplace solutions."
     In practice, oral fluid-based testing for drugs-of-abuse has proven to be
 most efficient for organizations looking to reduce workplace drug use.
 Research shows that oral fluid testing yields results that are comparable in
 accuracy to urine tests, and can detect the presence of virtually all drugs
 within minutes of consumption.  Avitar will continue to focus its marketing
 and sales efforts on its on-site ORALscreen(R) DRUGOMETER(TM).  ORALscreenLAB,
 however, presents a viable option to corporations wishing to step away from
 urine testing, but are not yet ready to implement on-site testing technology.
 
     About Avitar
     Avitar, Inc. develops, manufactures and markets innovative and proprietary
 products.  Their field includes the oral fluid diagnostic market, the disease
 and clinical testing market, and customized polyurethane applications used in
 the wound dressing industry.  Avitar manufactures ORALscreen(R), the world's
 first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse, as well
 as HYDRASORB(R), an absorbent topical dressing for moderate to heavy exudating
 wounds.  Avitar is also developing diagnostic strategies for disease and
 clinical testing in the estimated $25 billion in-vitro diagnostics market.
 Conditions targeted include influenza, diabetes, and pregnancy.  For more
 information, see Avitar's website at http://www.avitarinc.com.
 
     Safe Harbor Statement. This release contains forward looking statements
 that are subject to risks and uncertainties including the development and
 marketing of new applications and other risks that are detailed from time to
 time in the Company's filings with the Securities and Exchange Commission.  In
 view of such risks and uncertainties, the Company's actual results could
 differ materially from those anticipated in such forward looking statements.
 
     Product Information: ORALscreenLAB
     Based upon the most recent statistics published by Quest Diagnostics,
 Inc., one of the nations leading test laboratories, ORALscreenLAB tests for
 99% of drugs typically found in the private U.S. workplace sector.
 ORALscreenLab is an inclusive laboratory-based screen and GS/MS confirmation
 test.  The solution is available in the three versions shown below.
 
     * ORALscreen LAB5+
       Amphetamines: (Dexedrine(R)), MDA (Love Pill), MDEA (Eve)
       Methamphetamines: (Desoxyn(R)), MDMA, Ecstasy
       THC: Delta-9-tetrahydrocannabinol (CAS No. 1972-08-3)
       Cocaine: Benzoylecgonine, (Coke)
       Opiates: Morphine (Durapmorph(R)), Codeine (Methylmorphine), 6-AM,
       Hydrocodone (Vicodin(R)), Hydromorphone (Dilaudid(R)), Oxycodone
       (Oxycontin(R), Percoset(R)), Oxymorphone (Nurmophan(R)), Dihydrocodeine
       PCP: Phencyclidine (Angel Dust)
 
     * ORALscreen LAB7 -- Detects: All drugs tested by ORALscreenLAB5+, and
       Benzodiazepines: Alprazolam (Xanax(R)), Clonazepam (Klonopin(R)),
       Chlordiazepoxide (Librium(R)), Diazepam (Valium(R)), Lorazepam
       (Avitvan(R)), Temazepam(Restoril(R)), Oxazepam (Serax(R)),Nordiazepam
       (Tranxene(R))
       Propoxyphene: (Darvon(R))
 
     * ORALscreen LAB8 -- Detects: All drugs tested by ORALscreenLAB7, and
       Barbiturates: Amobarbital (Amytal(R)), Butabarbital (Butisol(R))
       Pentobarbital (Nembutal(R)), Phenobarbital (Luminal(R)), Secobarbital
       (Seconal(R)), Butalbital (Fiorinal(R))
 
 
      Company Contact:                     PR Contact:
      Peter Cholakis                       Maura Landry
      Avitar Inc.                          SHIFT Communications
      781-821-2440 x117                    617-681-1229
      pcholakis@avitarinc.com              mlandry@shiftcomm.com
 
 SOURCE  Avitar, Inc.